



Major Breakthroughs in Diabetic Animal Model Research

Guest Editors:

**Dr. Magdalena Chottova
Dvorakova**

Biomedical Center, Faculty of
Medicine in Pilsen, Charles
University, 323 00 Pilsen, Czech
Republic

Dr. Shashank Pandey

Biomedical Center, Faculty of
Medicine in Pilsen, Charles
University, 323 00 Pilsen, Czech
Republic

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editors

Dear Colleagues,

Diabetes mellitus is one of the most significant global health emergencies of the 21st century. According to a statistical analysis conducted by International Diabetes Federation in 2017, 451 million adult people have diabetes worldwide, and this number is expected to reach 693 million by 2045. WHO claimed that it will be the seventh leading cause of death worldwide in 2030. For these reasons, it is necessary to pay great attention to research on the processes occurring in the diabetic organism. Although research into the pathophysiology of this disease has been ongoing for more than 100 years, no effective and reliable therapy has yet been found. Animal models of individual types of diabetes played, and still play, a significant role in this research.

The aim of this Special Issue is to collect the recent updates on the use of animal models in diabetes research, including, the description of hitherto undescribed pathological processes or new therapeutic options. We welcome original research and review articles.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI